# REGULATION OF MYELOID PROGENITOR CELL DIFFERENTIATION

> **NIH NIH R01** · GLAXOSMITHKLINE · 1992 · $128,038

## Abstract

This application will investigate the relationships between
recombination growth factors and inhibitors in controlling myeloid
progenitor cell proliferation the understanding of the interactive
effects of these biomolecules is important to the ultimate clinical
use of these factors for biotherapy.  The interegulatory roles of
recombinant murine and human growth factors G-CSF, GM-CSF, M-CSF
(CSF1) Interleukin 3 and Interkeukin 1, and inhibitors, interferons
alpha, beta and gamma Tumor Necrosis Factor (TNF) and prostaglandin
E (PCE), in the control of murine and human hematopoietic
progenitor cell proliferation will be investigated.  A novel-PGE2
induced hematopoietic suppressor mechanism has been demonstrated
intact animals which has broad implications to suppressed
hematopoiesis in patients with Aplastic Anemia, Anemia of Chronic
Disease, and Leukemia.  The ability of growth factors to similarly
induce such a mechanism, or protect and/or override this mechanism
will be analyzed in intact animals and in in vitro cell cultures
A soluble inhibitor derived from bone marrow and spleens of mice
treated with PGE2 in vivo will be biochemically purified,
sequenced, cloned, and its mechanism of action determined.  The
capacity of PGE2 or the purified protein which mediates its effect,
to protect hematopoiesis, in animal models of lethal irradiation
and chemotherapy, will be tested in normal animals and tumor hosts.
The role of growth factors to potentiate survival will be
investigated.  The interrelationships between human accessory cell
factors, notably CSFs, PGE, IFNs and TNF with respect to cell
source, kinetics of release and effects upon Erythropoiesis and
Myelopoiesis will be studied in vitro using purified accessory cell
populations, high enriched progenitor cell populations, recombinant
factors, radioimmunoassays for PGE2 and in situ hybridization
techniques.  The potential regulatory effects of TGF beta on human
hematopoiesis will be investigated using in vitro clonal agar
methods.

## Key facts

- **NIH application ID:** 3171185
- **Project number:** 5R01CA033225-11
- **Recipient organization:** GLAXOSMITHKLINE
- **Principal Investigator:** Louis M Pelus
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1992
- **Award amount:** $128,038
- **Award type:** 5
- **Project period:** 1990-09-15 → 1993-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171185

## Citation

> US National Institutes of Health, RePORTER application 3171185, REGULATION OF MYELOID PROGENITOR CELL DIFFERENTIATION (5R01CA033225-11). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171185. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*